PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Cannabis Investing PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
Cannabis Investing PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
Cannabis Investing PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
Cannabis Investing PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
Cannabis Investing PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System
Cannabis Investing Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project
Cannabis Investing PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
Pharmaceutical Investing PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
